Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

450 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-03-31

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators will obtain a cohort of patients from multiple large cancer centers in China and try to unravel the efficacy of "radiotherapy combined with EGFR-TKI", which may provide some evidences for the treatment of stage III-inoperable NSCLC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

NCT04324164

Non-small Cell Lung Cancer

RECRUITING

A Retrospective Study of Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant Lung Cancer

NCT05934461

The Primary Study Metric is Progression-free Survival (PFS)

COMPLETED

Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC

NCT03074864

Non-small Cell Lung Cancer Epidermal Growth Factor Receptor

UNKNOWN PHASE2/PHASE3

Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer

NCT01724801

Brain Metastasis Non Small Cell Lung Cancer

COMPLETED PHASE3

A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

NCT04636593

Non Small Cell Lung Cancer Stage III NSCLC EGFR Activating Mutation

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The frequency of EGFR mutations in patients with stage III inoperable adenocarcinoma or non-squamous cell carcinoma is 17-31%, which is relatively low. Compared to patients with EGFR wild type, the efficacy of radiotherapy or chemo-radiotherapy may be different in EGFR mutant patients. Some small sample studies showed, compared with patients with EGFR wild type, patients with EGFR mutations have a lower risk of local recurrence and a higher risk of distant metastasis under the standard treatment for stage III lung cancer, which demonstrate the strength of systemic therapy may help. Radiotherapy combined with EGFR-Tyrosine kinase inhibitors(TKI) is a feasible treatment strategy. In view of the low mutation frequency and few prospective research results, the investigators try to explore the survival differences of three treatment strategies used in clinical practice based on the real world data. The investigators will obtain a cohort of patients from multiple large cancer centers in China and try to unravel the efficacy of "radiotherapy combined with EGFR-TKI", which may provide some evidences for the further study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non Small Cell Lung Cancer Stage III Non-small-cell Lung Cancer EGFR Mutation-Related Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Radiation(Chemo-radiation)

Patients in this group had been treated with definitive radiation/Chemo-radiation followed by no treatment until progression.

radiation or chemo-radiation

Intervention Type RADIATION

standard treatment for stage III lung cancer

radiation+EGFR-TKI

Patients in this group had been treated with one of the following three ways: 1) definitive radiation and concurrent EGFR-TKI followed by EGFR-TKI till progression; 2) EGFR-TKI followed by radiation and continue TKI util progression; 3) radiation and TKI thereafter until progression.

radiation or chemo-radiation

Intervention Type RADIATION

standard treatment for stage III lung cancer

EGFR-TKI Inhibitor

Intervention Type DRUG

the standard treatment for stage IV lung cancer with EGFR mutation

EGFR-TKI

Patients in this group had been treated with EGFR-TKI without any other treatment until progression.

EGFR-TKI Inhibitor

Intervention Type DRUG

the standard treatment for stage IV lung cancer with EGFR mutation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

radiation or chemo-radiation

standard treatment for stage III lung cancer

Intervention Type RADIATION

EGFR-TKI Inhibitor

the standard treatment for stage IV lung cancer with EGFR mutation

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

EGFR-TKI alone

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* histologically confirmed NSCLC with adenocarcinoma
* stage III (AJCC 7th edition)
* inoperable or refuse surgery
* EGFR-TKI mutation, specimen from tissue or blood